Intas Pharma launches first etanercept biosimilar

Intas Pharmaceuticals has launched INTACEPT, the first biosimilar to Amgen’s Enbrel (etanercept). INTACEPT has been launched in two strengths, 25mg in 0.5 ml and 50 mg in 1.0 ml preservative free solution, in easy to use pre-filled syringes.

According to the company, it is the first etanercept biosimilar manufactured in India and is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis, all debilitating autoimmune diseases.

Binish Chudgar, vice-chairman of the company said, “Etanercept is a fusion protein that is difficult to develop. INTACEPT is a further validation of our world-class R&D and manufacturing capabilities that bring global healthcare standards to Indian patients at a lower cost. Through INTACEPT, we are able to reduce the cost of treatment for patients to about half of the imported Enbrel.”

Intas launched its first biosimilar in the domestic market in 2004. With the launch of INTACEPT, the company now has nine biosimilar products in the market, including one monoclonal antibody MABTAS (rituximab), the largest indigenously development portfolio of biosimilar products.

Ref: Times of India, Published on Mar 27, 2015, 06.54 PM IST